Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 13
Submit an article Journal homepage
3,562
Views
7
CrossRef citations to date
0
Altmetric
Original Articles

A 2:1 randomized, open-label, phase II study of selinexor vs. physician’s choice in older patients with relapsed or refractory acute myeloid leukemia

Kendra Sweeta Moffitt Cancer Center, Tampa, FL, USACorrespondence[email protected]
View further author information
,
Bhavana Bhatnagarb Ohio State University, Columbus, OH, USAView further author information
,
Hartmut Döhnerc University of Ulm, Ulm, GermanyView further author information
,
Will Donnelland Sarah Cannon Cancer Center, Nashville, TN, USAView further author information
,
Olga Frankfurte Northwestern University, Chicago, IL, USAView further author information
,
Michael Heuserf Hannover Medical School, Hannover, GermanyView further author information
,
Vamsi Kotag Emory University, Atlanta, GA, USAView further author information
,
Hongtao Liuh University of Chicago, Chicago, IL, USAView further author information
,
Emmanuel Raffouxi Hôpital Saint-Louis, Paris, FranceView further author information
,
Gail J. Robozj Weill Cornell Medicine, New York, NY, USAView further author information
,
Christoph Rölligk Dresden University of Technology, Dresden, GermanyView further author information
,
Margaret M. Showell Johns Hopkins University, Baltimore, MD, USAView further author information
,
Stephen A. Strickland Jr.m Vanderbilt-Ingram Cancer Center, Nashville, TN, USAView further author information
,
Susana Vivesn ICO Badalona-Hospital Germans Trias i Pujol, Badalona, SpainView further author information
,
Shijie Tango Karyopharm Therapeutics, Newton, MA, USAView further author information
,
Thaddeus J. Ungero Karyopharm Therapeutics, Newton, MA, USAView further author information
,
Anita Joshio Karyopharm Therapeutics, Newton, MA, USAView further author information
,
Yao Shenp DarwinHealth Inc, New York, NY, USAView further author information
,
Mariano J. Alvarezp DarwinHealth Inc, New York, NY, USA;q Columbia University, New York, NY, USAView further author information
,
Andrea Califanoq Columbia University, New York, NY, USAView further author information
,
Marsha Crochiereo Karyopharm Therapeutics, Newton, MA, USAView further author information
,
Yosef Landesmano Karyopharm Therapeutics, Newton, MA, USAView further author information
,
Michael Kauffmano Karyopharm Therapeutics, Newton, MA, USAView further author information
,
Jatin Shaho Karyopharm Therapeutics, Newton, MA, USAView further author information
,
Sharon Shachamo Karyopharm Therapeutics, Newton, MA, USAView further author information
,
Michael R. Savonar Vanderbilt University, Nashville, TN, USAView further author information
&
Pau Montesinoss Departamento de Hematologia, Hospital Universitario y Politécnico La Fe, Valencia, Spain;t CIBERONC, Instituto de Salud Carlos III, Madrid, SpainORCID Iconhttps://orcid.org/0000-0002-3275-5593View further author information
ORCID Icon show all
Pages 3192-3203 | Received 30 Sep 2020, Accepted 21 Jun 2021, Published online: 29 Jul 2021

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.